stockrow
Friday 6 November 2026
Export CMMB’s income statement to Excel — free account
Chemomab Therapeutics Ltd. Sponsored ADR
CMMB Healthcare Biotechnology
- EPS
- +25.0%
- Free cash flow
- +47.9%
Quarter to June 2026, against a year earlier
1.33
0.08
+6.40%
Follow CMMB
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
6.41 | 10.31 | 9.08 | 10.49 |
+8 more quarters Free account |
Net Debt/EBITDA |
2.98 | 4.35 | 5.25 | 5.53 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.73 | 0.00 | 5.94 | 0.00 | |
Capex/Depreciation |
(0.14) | — | (0.04) | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | — | |
Free Cash Flow per Share |
(0.47) | 0.00 | (1.42) | 0.00 | |
Cash per Share |
0.84 | 1.01 | 1.33 | 0.41 | |
Shareholders Equity per Share |
1.09 | 1.34 | 1.58 | 0.45 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.09 | 1.34 | 1.58 | 0.45 | |
Free Cash Flow |
(3.75) | — | (11.13) | — | |
Working Capital |
8.40 | 10.36 | 11.95 | 10.79 | |
Capital Expenditures |
0.00 | — | 0.00 | — | |
Net Current Asset Value |
8.40 | 10.36 | 11.95 | 10.79 | |
| Other line items | |||||
Quick Ratio |
6.41 | 10.31 | 9.08 | 8.98 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.47) | 0.00 | (1.42) | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
2.27 | 2.56 | 1.75 | — | |
Average Payables |
0.32 | 0.35 | 0.56 | 0.29 | |
Average Assets |
10.68 | 12.31 | 15.39 | 16.63 | |
Average Common Equity |
9.19 | 10.54 | 12.94 | 13.77 | |
Capex to Sales |
0.00 | — | 0.00 | — |
Columns are period end dates · fundamentals updated 26 Oct 2026